 The objective of any investor is a simple one: to make money.While this objective couldnt be clearer, it is much harder putting it into action. How is one to spot the potential of a stock on a downward spiral or one which has been rising high yet still has more fuel in the tank? Or what about the investors holy grail; Catching a stock before it takes off and then reaping its multiplying rewards?TipRanks Stock Screener comes in handy here. The tool includes filters such as price target, analyst consensus and news sentiment, amongst others, to help investors get the lowdown on a stock.So, we opened up the Stock Screener to zoom in on 3 tickers that have the potential to soar over the next 12 months. And by soar, we mean soar till you can see them no more. The out of sight types with potential for triple-digit returns. Moreover, currently on the Street, these 3 choices all have a Strong Buy consensus rating. Lets have a look.RedHill Biopharma RDHLIt has been a busy few months for gastrointestinal disease specialist, RedHill Biopharma.In November, the biotech secured FDA approval for Talicia, the companys treatment for Helicobacter pylori infection in adults. The drugs approval marked the first instance of a rifabutin-based therapy receiving the FDAs blessing.The positive development followed Octobers announcement of a 36 million strategic investment by Cosmo Pharmaceuticals, which includes an exclusive license agreement for the U.S. rights to Aemcolo, Redhills treatment for travelers diarrhea, a condition bought on by non-invasive strains of E. coli in adults. The deal leaves Redhills balance sheet debt free and well positioned for the launch of Talicia.Nomuras Christopher Marai thinks Talicia is undervalued and argues that the company has what it takes to execute the drugs launch. The 4-star analyst said, RDHL has 40 sales reps, and its HQ in Raleigh, NC, and has been prepping for the Talicia launch for over three years. RDHL is actively targeting 10,000 HCPs and has relationships with top payers and PBMs, representing 80 of commercial lives. RDHL is capable of launching this drug in the U.S. without a partner and, thus, should be able to keep 90 margins. The ramp of the launch may be slow, but RDHL is already doing outreach.The company has several other treatments in the pipeline, including RHB-104, a treatment for Crohns disease, which showed positive top-line results from a Phase 3 trial. This led Marai to conclude that there is significant opportunity over the next 12 months.To this end, Marai reiterated a Buy rating on RedHill, alongside a price target of 28. This indicates upside potential of a massive 380. To watch Marais track record, click hereOnly two other analysts have thrown the hat in over the last three months with a view on the promising biopharma. Both, though, rate the stock a Buy, thus bestowing on RDHL a Strong Buy consensus rating. An average price target of 22.33, implies skyscraping upside potential of 283. See RedHill stock analysis on TipRanks Cabaletta Bio CABAFresh out of the box is newly listed biotech Cabaletta Bio. The micro-cap went public less than two months ago but is already drawing a small but vocal following on the Street.CABAs platform uses CAR T cell technology to selectively target B cell-mediated autoimmune diseases. The companys vision is to develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases.According to Cabaletta, the CABA platform has applicability for more than two dozen B cell-mediated autoimmune diseases and the company has several drugs already in the pipeline. Its lead program is DSG3-CAART, a treatment for mucosal pemphigus vulgaris mPV. The FDA has approved an IND investigational new drug application for the treatment, with clinical trials expected to start in 2020.Evercores Joshua Schimmer thinks there is strong rationale underlying CABAs target indications. The 5-star analyst said, CABA has presented strong preclinical data suggesting that CAAR-T therapies should have utility for autoimmune diseases. However, clinical results will be needed to determine if complete depletion of pathogenic B-cells without relapse a cure is possible without preconditioning, the effect of soluble antibodies on potential for cytokine release syndrome and risk of initial disease flares. In our view, the preclinical data has been impressive, and the company has been thoughtful about potential process changes which could mitigate these risks if they do arise.With this in mind, Schimmer initiated coverage on Cabaletta with an Outperform rating and set a price target of 25, implying huge upside potential of 147. To watch Schimmers track record, click hereOn the Street, there are currently only two other analysts tracking the fledgling biotech, both deeming CABA a Buy. Therefore, Cabaletta has a Strong Buy consensus rating. The average price target is 22, indicating gains of 117 could be in the cards over the next 12 months. See Cabaletta stock analysis on TipRanks Village Farms International Inc VFFBucking the trend this year is cannabis producer Village Farms. Unlike the general downturn in the cannabis industrys miserable 2019, VFFs share price is up by 84 year-to-date.What differentiates this company from other cannabis growers is VFFs background. The companys foray into the cannabis industry comes off the back of years growing and selling vegetables, and it has a reputation as a low-cost producer of tomatoes and cucumbers, amongst other produce.Village Farms has a majority stake in Pure Sunfarms, one of the single largest cannabis growing operations in the world. The company has applied its growing expertise and greenhouse equipment to the new venture, an investment that is already bearing fruit; Pure Sunfarms recently signed an agreement with the Alberta Gaming, Liquor Cannabis AGLC commission to supply recreational cannabis to licensed retailers in Alberta.Raymond James analyst Rahul Sarugaser thinks VFFs background bodes well for the future. The 4-atar analyst noted, Village Farms is leveraging more than 30 years of fresh produce cultivation experience30 years developing intimate knowledge of its greenhouses and region-specific climate to pursue opportunities in cannabis... From VFFs first announcement describing aspirations in the cannabis industryless than three years agoto the present, Pure Sunfarms has become the lowest cost greenhouse grower in Canada, averaging an all-in production cost of US0.48g C0.63g last quarter.Therefore, Sarugaser initiated coverage of Village Farms with an Outperform rating and price target of 8.36. Should the target be met over the next 12 months, gains of 40 could be in place. To watch Sarugasers track record, click hereSarugasers optimistic thesis is dwarfed by his colleagues target for the cannabis grower. A Strong Buy consensus rating breaks down into 5 Buys, with the average price target of 20.11 indicating upside potential of 237. See Village Farms stock-price forecast and analyst ratings To find good ideas for stocks trading at fair value or better, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. 